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tion in 2006 in the following counties: Vas (6.326 inhabitants/pharmacy), Pest (5.913
inhabitants/pharmacy) and Nógrád (5.855 inhabitants/pharmacy), while the small-
est: Bács-Kiskun (4.034 inhabitants/pharmacy), Békés (4.165 inhabitants/phar-
macy) and Somogy (4.218 inhabitants/pharmacy). In 2010 Nógrád (5.123 inhabit-
ants/pharmacy), Vas (4.632 inhabitants/pharmacy) and Pest (4.424 inhabitants/
pharmacy) counties had the largest catchment population, while Bács-Kiskun
(3.222 inhabitants/pharmacy), Békés (3.458 inhabitants/pharmacy) and Csongrád
(3.441 inhabitants/pharmacy) had the lowest. CONCLUSIONS: Between 2007-2010,
as the consequence of the increasing number of pharmacies, the average catch-
ment population of pharmacies decreased significantly. The regional differences
among counties did not change during the study period and remained high.
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OBJECTIVES: The value of a drug can be expressed as cost needed to increase a unit
of health. However, summarizing the economic value of a molecule with multiple
indications is a complex process. The COVET study was conducted to facilitate a
comprehensive economic evaluation of adalimumab across all approved
indications. METHODS: An algorithm was developed to estimate the total eco-
nomic value of adalimumab. This value was calculated as the sum of the incre-
mental cost-utility ratios for treating rheumatoid arthritis, psoriatic arthritis, an-
kylosing spondylitis, Crohn’s disease, and psoriasis from a Italian National Health
Care (NHC) perspective. Estimates of the cost per quality-adjusted life year (QALY)
gained by using adalimumab instead of standard therapy were derived from pre-
viously developed economic models. The sum was weighted by the prevalence of
each of the diseases considered. Through a systematic literature review, the cost
per QALY gained by using other anti-TNF drugs was extrapolated. Subsequently, a
Boston matrix was developed to establish the relationship between demand and
health supply. A one-way sensitivity analysis (SA) performed to assess the robust-
ness of the results. RESULTS: The total economic value of adalimumab in Italy
amounted to €34,750 per QALY. The sensitivity analysis showed a cost per QALY
gained ranging between €27,447 and €40,412. The analysis of the Boston matrix
indicated that, with the exception of psoriasis, the cost per QALY gained by using
adalimumab instead of standard therapy was below the common WTP threshold.
In comparison with innovative molecules, the total economic value of adalimumab
was positive and sustainable. CONCLUSIONS: This study provides an estimate of
the cost-effectiveness of adalimumab across all approved indications that is below
the threshold value for health care interventions. The results should encourage
decision makers to facilitate patient access to this cost-effective treatment. They
may also promote research to develop innovative molecules that are even more
cost-effective.
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OBJECTIVES: As treatments trend towards personalized medicine for conditions
with certain genetic expressions, new opportunities exist for diagnostic tests to
change the standard of care and demonstrate positive economic impact to payers.
A systematic review of the role of economic evaluation to the coverage and pay-
ment of novel diagnostics has not yet been performed. The authors undertook this
analysis to examine what evidence exists to document the use of health economic
rationale and modeling to impact reimbursement and market access outcomes for
diagnostics. METHODS: A systematic review of published literature related to the
reimbursement and health technology assessment of diagnostics was conducted.
In addition, published coverage policies and HTAs in the US, UK, and Germany
related to personalized medicine diagnostics commercialized within the last de-
cade were reviewed. Policies and HTAs were graded to document the level of im-
pact economics played to decision-outcomes, if reported. Where specific refer-
ences were not made, a review of the citations referenced was conducted to see if
economic papers or models were included within their decision-framework.
RESULTS: Most published personalized medicine diagnostic coverage policies and
HTAs reference both clinical and economic evidence, though clinical data is prior-
itized. Of the policies analyzed, national HTA groups that reviewed novel diagnos-
tics or products with companion diagnostics, were most explicit in their consider-
ation of clinical and economic data. US payers were less likely to explicitly
reference economic data. CONCLUSIONS: As treatments are becoming more and
more dependent on companion diagnostic tests to influence treatment of disease
in a variety of subgroups, the processes by which diagnostics are approved, cov-
ered, and reimbursed will become more scrutinized. More standardized and trans-
parent incorporation of economic rationale and modeling into payer coverage,
payment, and HTA evaluation processes would clarify expectations and help com-
panies plan for HEOR activities.
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OBJECTIVES: With the formation of Clinical Commissioning Groups (CCGs) GP
Practices will come together to commission services for their local populations.
However, freedoms to be delegated from the Clinical Commissioning board may
mean that considerable ‘command and control’ will still be exerted from the cen-
tre. Secondary and primary research was undertaken to gain insight into how
devolved locality based commissioning is likely to impact on access to medicines.
METHODS: We reviewed 35 first wave CCGs in terms of population coverage, fi-
nancial stability and current Primary care Trust (PCT) activities in relation to Prac-
tice based commissioning. We then interviewed 5 NHS Experts to assess whether
these CCGs would be allowed the aspirational freedoms referred to in the 2012
Health and Social Care Act- in particular prescribing freedoms formerly under the
guidance of PCTs. Various information sources were used Care Quality Commis-
sion, Audit Commission, and Health Select Committee reports to support the in-
terpretation of the findings. RESULTS: The selected CCGs represented an homoge-
neous group of practices in that they had previously demonstrated financial
stewardship and collaborative working with their ‘host’ PCTs. Many CCGs had been
devolved the Commissioning budget by their PCTs and were routinely involved in
setting up medicines management protocols with their provider hospitals. Almost
half of the CCGs had coterminous medicines management contracts shared with
their PCTs. NHS experts raised issues around corporate and clinical governance
and how practices would fundamentally want to take on the devolved financial
responsibilities.CONCLUSIONS:The NHS reforms mean that £60 Billion of the total
health care budget will be under the control of CCGs. PCTs and Strategic Health
Authorities will be abolished and with a watered down role for NICE postcode
variation may be rife; access to medicines will continue to be fraught with many
layers of decision making and further delays.
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OBJECTIVES: Active domestic pharmacovigilance programs are necessary as ad-
verse drug reaction (ADR) data from other countries may overlook safety patterns
in local populations. The success of any surveillance system relies upon active
participation of reporters. The objective of this study was to describe pharmacist
reporting of suspected ADRs in Qatar to inform policy recommendations to the
Supreme Council of Health. METHODS: A 27-item survey was developed following
comprehensive literature review of relevant published research. Questions encom-
passed broad domains including: pharmacist knowledge of and experiences in
reporting suspected ADRs; attitudes towards health professional pharmacovigi-
lance roles; perceived barriers and facilitators to reporting; and recommendations
for improvements in this process. The web-based survey was formatted for elec-
tronic delivery and response for self-administration in English or Arabic by a con-
venience sample of over 500 Qatar pharmacists. RESULTS: The survey remained
open for two months between April 30 and June 30, 2011. Of the 142 (25%) total
responses, 116 (81.6%) surveys were completed beyond demographic data and in-
cluded information about prior suspected ADR reporting experiences. Knowledge
of ADR terminology and reporting purpose among the 116 (20%) responding phar-
macists was high, but only 34 (30%) had ever made a suspected ADR report in Qatar.
Most respondents expressed positive attitudes towards pharmacist roles in phar-
macovigilance activities, but inability to recognize a potential ADR or subsequently
access a reporting form were perceived barriers, with enhanced training and effi-
ciency in report submission corresponding identified facilitators to future partici-
pation. Hospital pharmacists were 7 times more likely than ambulatory-care based
pharmacists to have reported a suspected ADR in Qatar. CONCLUSIONS: Pharma-
cists in Qatar are willing to engage in pharmacovigilance activities if supported by
increased training and transparency in the reporting process. A national infra-
structure with capacity to collect and manage suspected ADR reports and promote
patient and medication safety is exigent.
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OBJECTIVES: In January 2011, the act for restructuring the pharmaceutical market
(“AMNOG”) was introduced in Germany. We analyzed the effects one year after
AMNOG’s implementation in an empirical study. The research focused on survey-
ing affected stakeholders, systematically summarizing their experiences, and
identifying topics of controversy. METHODS: Stakeholders were defined based on
statements during the AMNOG legislation: Payors, Pharmaceutical Industry, Na-
tional Regulatory Bodies, Scientific Experts, Patients, Care Providers, Politicians,
Pharmacies and External Service Providers. The benefit assessement process was
structured into 6 topics: Market Launch, Early Benefit Assessment, Price Negotia-
tions, Arbitration Procedure, Cost-Benefit Analysis and Process. 45 experts partic-
ipated in the structured survey (26% response rate), which consisted of closed
questions supplemented by optional open-ended questions (total 47 items). De-
scriptive statistical and dissimilarity analyses were performed. RESULTS: Between
the 9 stakeholder groups, several items were highly controversial: negotiation po-
sition of statutory health insurances (“GKV-Spitzenverband”) in rebate level nego-
tiations (distance index L21.17), use of European price reference in the arbitration
process (L21.08) and several others such as transparency of the benefit assess-
ment process (L20.95). Different response profiles were observed between stake-
holders but they yielded relatively low dissimilarities on cost-benefit assessment.
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